Access Statistics for Iain M. Cockburn
Author contact details at EconPapers.
| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Mixed Poisson Regression Model for Analysis of Patent Data |
0 |
0 |
0 |
290 |
10 |
24 |
133 |
1,448 |
| Are All Patent Examiners Equal? The Impact of Examiner Characteristics |
3 |
9 |
32 |
317 |
11 |
34 |
134 |
1,649 |
| Balancing Incentives: The Tension Between Basic and Applied Research |
2 |
8 |
26 |
375 |
9 |
24 |
99 |
1,579 |
| Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins |
0 |
0 |
0 |
0 |
17 |
47 |
212 |
1,980 |
| Do Patents Matter?: Empirical Evidence after GATT |
1 |
3 |
20 |
260 |
1 |
7 |
41 |
669 |
| Entry, Exit and Patenting in the Software Industry |
1 |
3 |
19 |
139 |
7 |
22 |
87 |
363 |
| Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs |
0 |
4 |
12 |
91 |
4 |
11 |
39 |
299 |
| Generics and New Goods in Pharmaceutical Price Indexes |
1 |
9 |
44 |
194 |
18 |
58 |
206 |
819 |
| Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital |
0 |
6 |
29 |
202 |
2 |
12 |
97 |
600 |
| Hedonic Analysis of Arthritis Drugs |
0 |
0 |
7 |
144 |
1 |
4 |
22 |
911 |
| Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents |
5 |
11 |
42 |
276 |
10 |
30 |
126 |
820 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
1 |
4 |
149 |
2 |
12 |
60 |
1,537 |
| Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers |
1 |
2 |
4 |
36 |
3 |
4 |
10 |
401 |
| Measuring competence?: exploring firm effects in pharmaceutical research |
7 |
9 |
51 |
364 |
17 |
32 |
144 |
745 |
| Not Invented Here? Innovation in Company Towns |
3 |
7 |
37 |
37 |
7 |
19 |
41 |
41 |
| Patent Thickets, Licensing and Innovative Performance |
0 |
3 |
31 |
48 |
7 |
11 |
53 |
60 |
| Patent thickets, licensing and innovative performance |
16 |
17 |
17 |
17 |
2 |
5 |
5 |
5 |
| Patents and the Survival of Internet-related IPOs |
0 |
4 |
18 |
57 |
1 |
9 |
35 |
144 |
| Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry |
1 |
2 |
9 |
66 |
1 |
7 |
31 |
113 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
1 |
2 |
17 |
87 |
1 |
3 |
33 |
191 |
| Public-Private Interaction and the Productivity of Pharmaceutical Research |
3 |
5 |
16 |
142 |
8 |
17 |
85 |
561 |
| Racing or spilling?: the determinants of research productivity in ethical drug discovery |
0 |
1 |
5 |
39 |
1 |
4 |
22 |
113 |
| Racing to invest?: the dynamics of competition in ethical drug discovery |
0 |
2 |
24 |
188 |
2 |
9 |
50 |
350 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
0 |
0 |
1 |
5 |
7 |
37 |
323 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry |
1 |
5 |
34 |
278 |
8 |
32 |
112 |
622 |
| Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery |
0 |
3 |
11 |
120 |
1 |
9 |
33 |
215 |
| The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research |
1 |
2 |
20 |
277 |
10 |
32 |
148 |
1,644 |
| University Research, Industrial R&D, and the Anchor Tenant Hypothesis |
3 |
5 |
29 |
178 |
6 |
16 |
84 |
603 |
| Total Working Papers |
50 |
123 |
558 |
4,372 |
172 |
501 |
2,179 |
18,805 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery |
3 |
3 |
23 |
179 |
8 |
17 |
154 |
712 |
| Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach |
0 |
0 |
0 |
0 |
4 |
10 |
86 |
677 |
| Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins |
1 |
10 |
36 |
309 |
1 |
18 |
81 |
866 |
| Faster, smaller, cheaper: an hedonic price analysis of PDAs |
1 |
2 |
6 |
7 |
2 |
6 |
26 |
32 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
2 |
14 |
160 |
1 |
10 |
43 |
640 |
| Generics and New Goods in Pharmaceutical Price Indexes: Reply |
0 |
0 |
0 |
25 |
0 |
0 |
6 |
122 |
| Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents |
2 |
3 |
16 |
159 |
3 |
10 |
47 |
518 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
2 |
2 |
5 |
15 |
4 |
7 |
35 |
175 |
| New Pills for Poor People? Empirical Evidence after GATT |
3 |
10 |
33 |
141 |
6 |
19 |
62 |
281 |
| Opportunity costs and entrepreneurial activity |
2 |
4 |
25 |
62 |
3 |
9 |
39 |
116 |
| Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry |
3 |
6 |
19 |
19 |
6 |
11 |
34 |
34 |
| Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery |
0 |
0 |
0 |
0 |
3 |
8 |
31 |
466 |
| Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research |
4 |
10 |
25 |
129 |
4 |
10 |
44 |
282 |
| Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery |
4 |
6 |
39 |
347 |
10 |
18 |
85 |
978 |
| The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems |
0 |
1 |
8 |
77 |
1 |
4 |
33 |
274 |
| Total Journal Articles |
25 |
59 |
249 |
1,629 |
56 |
157 |
806 |
6,173 |
|
|
LogEc is hosted by the
Swedish Business School at Örebro University.